Attenuation of posttraumatic muscle catabolism and osteopenia by long-term growth hormone therapy

David W. Hart, David N. Herndon, Gordon Klein, Steven B. Lee, Mario Celis, Subburaman Mohan, David L. Chinkes, Steven E. Wolf

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Objective To determine whether the beneficial effects of growth hormone persist throughout the prolonged hypermetabolic and hypercatabolic response to severe burn. Summary Background Data The hypermetabolic response to severe burn is associated with increased energy expenditure, insulin resistance, immunodeficiency, and whole body catabolism that persists for months after injury. Growth hormone is a potent anabolic agent and salutary modulator of posttraumatic metabolic responses. Methods Seventy-two severely burned children were enrolled in a placebo-controlled double-blind trial investigating the effects of growth hormone (0.05 mg/kg per day) on muscle accretion and bone growth. Drug or placebo treatment began on discharge from the intensive care unit and continued for 1 year after burn. Total body weight, height, dual-energy x-ray absorptiometry, indirect calorimetry, and hormone values were measured at discharge, then at 6 months, 9 months, and 12 months after burn. Results were compared between groups. Results Growth hormone subjects gained more weight than placebo subjects at the 9-month study point; this disparity in weight gain continued to expand throughout the remainder of the study. Height also increased in the growth hormone group compared with controls at 12 months. Change in lean body mass was greater in those treated with growth hormone at 6, 9, and 12 months. Bone mineral content was increased at 9 and 12 months; this was associated with higher parathormone levels. Conclusions Low-dose recombinant human growth hormone successfully abates muscle catabolism and osteopenia induced by severe burn.

Original languageEnglish (US)
Pages (from-to)827-834
Number of pages8
JournalAnnals of Surgery
Volume233
Issue number6
DOIs
StatePublished - 2001

Fingerprint

Metabolic Bone Diseases
Growth Hormone
Muscles
Placebos
Therapeutics
Anabolic Agents
Indirect Calorimetry
Body Height
Human Growth Hormone
Bone Development
Parathyroid Hormone
Bone Density
Energy Metabolism
Weight Gain
Intensive Care Units
Insulin Resistance
Body Weight
X-Rays
Hormones
Weights and Measures

ASJC Scopus subject areas

  • Surgery

Cite this

Attenuation of posttraumatic muscle catabolism and osteopenia by long-term growth hormone therapy. / Hart, David W.; Herndon, David N.; Klein, Gordon; Lee, Steven B.; Celis, Mario; Mohan, Subburaman; Chinkes, David L.; Wolf, Steven E.

In: Annals of Surgery, Vol. 233, No. 6, 2001, p. 827-834.

Research output: Contribution to journalArticle

Hart, DW, Herndon, DN, Klein, G, Lee, SB, Celis, M, Mohan, S, Chinkes, DL & Wolf, SE 2001, 'Attenuation of posttraumatic muscle catabolism and osteopenia by long-term growth hormone therapy', Annals of Surgery, vol. 233, no. 6, pp. 827-834. https://doi.org/10.1097/00000658-200106000-00013
Hart, David W. ; Herndon, David N. ; Klein, Gordon ; Lee, Steven B. ; Celis, Mario ; Mohan, Subburaman ; Chinkes, David L. ; Wolf, Steven E. / Attenuation of posttraumatic muscle catabolism and osteopenia by long-term growth hormone therapy. In: Annals of Surgery. 2001 ; Vol. 233, No. 6. pp. 827-834.
@article{7fc97189a5b445ce8dcb87572cdbacdb,
title = "Attenuation of posttraumatic muscle catabolism and osteopenia by long-term growth hormone therapy",
abstract = "Objective To determine whether the beneficial effects of growth hormone persist throughout the prolonged hypermetabolic and hypercatabolic response to severe burn. Summary Background Data The hypermetabolic response to severe burn is associated with increased energy expenditure, insulin resistance, immunodeficiency, and whole body catabolism that persists for months after injury. Growth hormone is a potent anabolic agent and salutary modulator of posttraumatic metabolic responses. Methods Seventy-two severely burned children were enrolled in a placebo-controlled double-blind trial investigating the effects of growth hormone (0.05 mg/kg per day) on muscle accretion and bone growth. Drug or placebo treatment began on discharge from the intensive care unit and continued for 1 year after burn. Total body weight, height, dual-energy x-ray absorptiometry, indirect calorimetry, and hormone values were measured at discharge, then at 6 months, 9 months, and 12 months after burn. Results were compared between groups. Results Growth hormone subjects gained more weight than placebo subjects at the 9-month study point; this disparity in weight gain continued to expand throughout the remainder of the study. Height also increased in the growth hormone group compared with controls at 12 months. Change in lean body mass was greater in those treated with growth hormone at 6, 9, and 12 months. Bone mineral content was increased at 9 and 12 months; this was associated with higher parathormone levels. Conclusions Low-dose recombinant human growth hormone successfully abates muscle catabolism and osteopenia induced by severe burn.",
author = "Hart, {David W.} and Herndon, {David N.} and Gordon Klein and Lee, {Steven B.} and Mario Celis and Subburaman Mohan and Chinkes, {David L.} and Wolf, {Steven E.}",
year = "2001",
doi = "10.1097/00000658-200106000-00013",
language = "English (US)",
volume = "233",
pages = "827--834",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Attenuation of posttraumatic muscle catabolism and osteopenia by long-term growth hormone therapy

AU - Hart, David W.

AU - Herndon, David N.

AU - Klein, Gordon

AU - Lee, Steven B.

AU - Celis, Mario

AU - Mohan, Subburaman

AU - Chinkes, David L.

AU - Wolf, Steven E.

PY - 2001

Y1 - 2001

N2 - Objective To determine whether the beneficial effects of growth hormone persist throughout the prolonged hypermetabolic and hypercatabolic response to severe burn. Summary Background Data The hypermetabolic response to severe burn is associated with increased energy expenditure, insulin resistance, immunodeficiency, and whole body catabolism that persists for months after injury. Growth hormone is a potent anabolic agent and salutary modulator of posttraumatic metabolic responses. Methods Seventy-two severely burned children were enrolled in a placebo-controlled double-blind trial investigating the effects of growth hormone (0.05 mg/kg per day) on muscle accretion and bone growth. Drug or placebo treatment began on discharge from the intensive care unit and continued for 1 year after burn. Total body weight, height, dual-energy x-ray absorptiometry, indirect calorimetry, and hormone values were measured at discharge, then at 6 months, 9 months, and 12 months after burn. Results were compared between groups. Results Growth hormone subjects gained more weight than placebo subjects at the 9-month study point; this disparity in weight gain continued to expand throughout the remainder of the study. Height also increased in the growth hormone group compared with controls at 12 months. Change in lean body mass was greater in those treated with growth hormone at 6, 9, and 12 months. Bone mineral content was increased at 9 and 12 months; this was associated with higher parathormone levels. Conclusions Low-dose recombinant human growth hormone successfully abates muscle catabolism and osteopenia induced by severe burn.

AB - Objective To determine whether the beneficial effects of growth hormone persist throughout the prolonged hypermetabolic and hypercatabolic response to severe burn. Summary Background Data The hypermetabolic response to severe burn is associated with increased energy expenditure, insulin resistance, immunodeficiency, and whole body catabolism that persists for months after injury. Growth hormone is a potent anabolic agent and salutary modulator of posttraumatic metabolic responses. Methods Seventy-two severely burned children were enrolled in a placebo-controlled double-blind trial investigating the effects of growth hormone (0.05 mg/kg per day) on muscle accretion and bone growth. Drug or placebo treatment began on discharge from the intensive care unit and continued for 1 year after burn. Total body weight, height, dual-energy x-ray absorptiometry, indirect calorimetry, and hormone values were measured at discharge, then at 6 months, 9 months, and 12 months after burn. Results were compared between groups. Results Growth hormone subjects gained more weight than placebo subjects at the 9-month study point; this disparity in weight gain continued to expand throughout the remainder of the study. Height also increased in the growth hormone group compared with controls at 12 months. Change in lean body mass was greater in those treated with growth hormone at 6, 9, and 12 months. Bone mineral content was increased at 9 and 12 months; this was associated with higher parathormone levels. Conclusions Low-dose recombinant human growth hormone successfully abates muscle catabolism and osteopenia induced by severe burn.

UR - http://www.scopus.com/inward/record.url?scp=0034980444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034980444&partnerID=8YFLogxK

U2 - 10.1097/00000658-200106000-00013

DO - 10.1097/00000658-200106000-00013

M3 - Article

VL - 233

SP - 827

EP - 834

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 6

ER -